APIM Therapeutics

📍 Risa, Norway🗓 Founded 2010👥 8 employees💰 Last funded Jun 2021
Pharmaceutical Manufacturing🌐 apimtherapeutics.com
Website LinkedIn
APIM Therapeutics is a venture capital financed Norwegian biotech company focusing on the development of novel treatments in the fields of oncology and inflammation. Our lead drug, ATX-101, is a first-in-class peptide drug candidate targeting a novel therapeutic intervention point involved in cellular stress defense mechanisms. ATX-101 is currently being tested in a phase I study in patients with advanced solid tumors.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2010
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Norway
1
Frequently asked questions
Who invested in APIM Therapeutics?
APIM Therapeutics has 1 investors on record on gritt.io.
When did APIM Therapeutics last raise funding?
The most recent investment in APIM Therapeutics recorded on gritt.io was in June 2021.
When was APIM Therapeutics founded?
APIM Therapeutics was founded in 2010.
What industry is APIM Therapeutics in?
APIM Therapeutics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is APIM Therapeutics based?
APIM Therapeutics is headquartered in Risa, Norway.